JP2020512975A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512975A5 JP2020512975A5 JP2019552849A JP2019552849A JP2020512975A5 JP 2020512975 A5 JP2020512975 A5 JP 2020512975A5 JP 2019552849 A JP2019552849 A JP 2019552849A JP 2019552849 A JP2019552849 A JP 2019552849A JP 2020512975 A5 JP2020512975 A5 JP 2020512975A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- crystal form
- peak
- crystalline form
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims 24
- 238000000634 powder X-ray diffraction Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 2
- -1 4-methyl-1,4-diazepan-1-yl Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- BFQOYWRISQXBBA-UHFFFAOYSA-N cinnoline-6-carboxamide Chemical compound N1=NC=CC2=CC(C(=O)N)=CC=C21 BFQOYWRISQXBBA-UHFFFAOYSA-N 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022201582A JP2023126708A (ja) | 2017-03-28 | 2022-12-16 | Ｐｏｌ１阻害剤の新規な結晶形態 |
| JP2024218994A JP2025060702A (ja) | 2017-03-28 | 2024-12-13 | Ｐｏｌ１阻害剤の新規な結晶形態 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477746P | 2017-03-28 | 2017-03-28 | |
| US62/477,746 | 2017-03-28 | ||
| US201762491635P | 2017-04-28 | 2017-04-28 | |
| US62/491,635 | 2017-04-28 | ||
| PCT/US2018/024898 WO2018183540A1 (en) | 2017-03-28 | 2018-03-28 | Novel crystal forms of a pol1 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022201582A Division JP2023126708A (ja) | 2017-03-28 | 2022-12-16 | Ｐｏｌ１阻害剤の新規な結晶形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512975A JP2020512975A (ja) | 2020-04-30 |
| JP2020512975A5 true JP2020512975A5 (enExample) | 2021-05-06 |
Family
ID=63676829
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552849A Pending JP2020512975A (ja) | 2017-03-28 | 2018-03-28 | Ｐｏｌ１阻害剤の新規な結晶形態 |
| JP2022201582A Pending JP2023126708A (ja) | 2017-03-28 | 2022-12-16 | Ｐｏｌ１阻害剤の新規な結晶形態 |
| JP2024218994A Pending JP2025060702A (ja) | 2017-03-28 | 2024-12-13 | Ｐｏｌ１阻害剤の新規な結晶形態 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022201582A Pending JP2023126708A (ja) | 2017-03-28 | 2022-12-16 | Ｐｏｌ１阻害剤の新規な結晶形態 |
| JP2024218994A Pending JP2025060702A (ja) | 2017-03-28 | 2024-12-13 | Ｐｏｌ１阻害剤の新規な結晶形態 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11912706B2 (enExample) |
| EP (1) | EP3601286A4 (enExample) |
| JP (3) | JP2020512975A (enExample) |
| CN (2) | CN115583948A (enExample) |
| BR (1) | BR112019020058A2 (enExample) |
| CA (1) | CA3057741A1 (enExample) |
| WO (1) | WO2018183540A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| US11912706B2 (en) | 2017-03-28 | 2024-02-27 | Pimera, Inc. | Crystal forms of a POL1 inhibitor |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1042801A (en) | 1909-10-28 | 1912-10-29 | Isidor Kitsee | Protecting kinematographic films. |
| NL7709746A (nl) | 1976-09-09 | 1978-03-13 | Hoechst Ag | Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen. |
| DE2929414A1 (de) | 1979-07-20 | 1981-02-05 | Hoechst Ag | Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung |
| DE3502689A1 (de) | 1985-01-26 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Elektrophotographisches aufzeichnungsmaterial |
| DE19509043A1 (de) | 1995-03-03 | 1996-09-05 | Bayer Ag | Cyanierung von Doppelbindungssystemen |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| ATE319713T1 (de) | 2000-10-03 | 2006-03-15 | Bristol Myers Squibb Co | Amino- substituierte tetracyclische verbindungen die als entzündungshemmende mittel nützlich sind, und diese enthaltende arzneimittel. |
| US7354916B2 (en) | 2003-04-07 | 2008-04-08 | Cylene Pharmaceuticals | Substituted quinobenzoxazine analogs |
| US7507727B2 (en) | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
| KR100944600B1 (ko) | 2003-04-07 | 2010-02-25 | 사일린 파마슈티칼스, 인크 | 치환된 퀴노벤족사진 유사체 |
| US7652134B2 (en) | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
| EP1802306A2 (en) | 2004-09-17 | 2007-07-04 | Cylene Pharmaceuticals, Inc. | Quinolone analog as cell proliferation inhibitors |
| EP1874731A4 (en) | 2005-04-15 | 2009-08-05 | Cylene Pharmaceuticals Inc | CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION |
| US7816524B2 (en) | 2005-08-05 | 2010-10-19 | Cylene Pharmaceuticals, Inc. | Methods of preparing quinolone analogs |
| EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
| US8142909B2 (en) | 2006-02-10 | 2012-03-27 | Universal Display Corporation | Blue phosphorescent imidazophenanthridine materials |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| WO2008060693A2 (en) | 2006-05-17 | 2008-05-22 | Cylene Pharmaceuticals, Inc. | Tetracyclic imidazole analogs |
| CN101888780B (zh) | 2007-10-05 | 2014-08-13 | 生华生物科技股份有限公司 | 喹诺酮类似物及其相关方法 |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 |
| US8368062B2 (en) | 2008-11-03 | 2013-02-05 | Lg Chem, Ltd. | Nitrogen-containing heterocyclic compound and organic electronic device using the same |
| US8124770B2 (en) | 2009-04-01 | 2012-02-28 | Beatriz Zayas | Fluorescent cellular markers |
| CN101781312B (zh) | 2009-12-30 | 2012-09-26 | 中国科学院广州生物医药与健康研究院 | 一种吲哚衍生物的合成方法 |
| WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| KR101567610B1 (ko) | 2010-11-04 | 2015-11-09 | 주식회사 엘지화학 | 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자 |
| SG11201400988SA (en) | 2011-10-21 | 2014-07-30 | Glaxosmithkline Llc | Compounds and methods for enhancing innate immune responses |
| KR101561730B1 (ko) | 2012-02-06 | 2015-10-22 | 주식회사 엘지화학 | 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자 |
| WO2015079411A1 (en) | 2013-11-28 | 2015-06-04 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
| US9758518B2 (en) * | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| RS57493B1 (sr) | 2014-05-09 | 2018-10-31 | Pimera Inc | Novi sastavi, upotrebe i metode za njihovo spravljanje |
| CN106349244B (zh) * | 2015-07-13 | 2018-07-27 | 首都医科大学 | 苯并咪唑并喹唑啉二甲氧苯氧乙酰-AA-OBzl，其合成，活性和应用 |
| CA3005730A1 (en) | 2015-11-20 | 2017-05-26 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
| US11912706B2 (en) | 2017-03-28 | 2024-02-27 | Pimera, Inc. | Crystal forms of a POL1 inhibitor |
-
2018
- 2018-03-28 US US16/497,724 patent/US11912706B2/en active Active
- 2018-03-28 CA CA3057741A patent/CA3057741A1/en active Pending
- 2018-03-28 EP EP18775916.2A patent/EP3601286A4/en active Pending
- 2018-03-28 CN CN202210899067.8A patent/CN115583948A/zh active Pending
- 2018-03-28 WO PCT/US2018/024898 patent/WO2018183540A1/en not_active Ceased
- 2018-03-28 CN CN201880035566.4A patent/CN110709400A/zh active Pending
- 2018-03-28 JP JP2019552849A patent/JP2020512975A/ja active Pending
- 2018-03-28 BR BR112019020058-4A patent/BR112019020058A2/pt not_active Application Discontinuation
-
2022
- 2022-12-16 JP JP2022201582A patent/JP2023126708A/ja active Pending
-
2024
- 2024-08-05 US US18/794,589 patent/US20250243200A1/en active Pending
- 2024-12-13 JP JP2024218994A patent/JP2025060702A/ja active Pending